Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients.
about
Identification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head and neck squamous cell carcinomaHer-2 immunohistochemical expression in oral squamous cell carcinomas is associated with polysomy of chromosome 17, not Her-2 amplification.Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cellsWest Nile alternative open reading frame (N-NS4B/WARF4) is produced in infected West Nile Virus (WNV) cells and induces humoral response in WNV infected individuals.EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC.Epidermal growth factor receptor gene copy number aberration at the primary tumour is significantly associated with extracapsular spread in oral cancer.In vivo invasion of head and neck squamous cell carcinoma cells does not require macrophages.Emerging drugs to treat squamous cell carcinomas of the head and neck.Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma.Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.Epidermal growth factor receptor inhibition and non-small cell lung cancer.Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic miceMalignancies of the head and neck: the role for molecular targeted agents.Upregulation of epidermal growth factor receptor 4 in oral leukoplakiaIdentification of potential therapeutic target genes and mechanisms in head and neck squamous cell carcinoma by bioinformatics analysis.Aberrant kinase signaling: lessons from head and neck cancer.Potassium increases the antitumor effects of ascorbic acid in breast cancer cell lines in vitro.ErbB receptors in the biology and pathology of the aerodigestive tractEGFR family: structure physiology signalling and therapeutic targets.A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.Potential of ErbB4 antibodies for cancer therapy.Epidermal growth factor receptor imaging in human head and neck cancer xenografts.HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.ErbB-4 and TNF-alpha converting enzyme localization to membrane microdomains.Inhibition of TGF-β and EGF pathway gene expression and migration of oral carcinoma cells by mucosa-associated lymphoid tissue 1.Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients.EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/α-β catenins complex and multiple ErbB receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas.Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers.HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.Spontaneous immunogenicity of ribosomal P0 protein in patients with benign and malignant breast lesions and delay of mammary tumor growth in P0-vaccinated mice.Critical role for D-type cyclins in cellular transformation induced by E6/E7 of human papillomavirus type 16 and E6/E7/ErbB-2 cooperation.Secretase-dependent tyrosine phosphorylation of Mdm2 by the ErbB-4 intracellular domain fragment.Synthesis and evaluation of MR probes for targeted-reporter imaging.A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.Immunohistochemical expression patterns of the HER4 receptors in normal mucosa and in laryngeal squamous cell carcinomas: antioncogenic significance of the HER4 protein in laryngeal squamous cell carcinoma.Comparison of tissue transglutaminase 2 and bone biological markers osteocalcin, osteopontin and sclerostin expression in human osteoporosis and osteoarthritis.Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas.
P2860
Q28385950-1865AA8E-AE76-44DF-84C8-A8B1A159ED3CQ33611282-1348CDEE-A468-459C-874E-D60410016E74Q33645792-D9D06F32-ED43-4713-A610-CD618ADE247EQ34313216-86FC37E2-A237-42A0-A820-CA3B8B8C4C31Q34618994-A37D2732-84F3-4985-8F4B-35A029ABE09FQ34619329-53C83D1C-375C-421A-BC74-DAC6C950AA1AQ34621876-72F39F64-9C10-4CBA-A009-DC0B26D0D793Q35071481-29AF05D3-6CDB-40DF-A11B-9A78C2624678Q35098322-55E6449A-E012-4ABF-8CF8-86D0ACEC8CF0Q35912079-CF77E029-3DCE-429D-9B24-22307D09AEFFQ36400027-AFA5BC46-4177-4BDA-B00E-5035FF11DD7EQ36504349-AA3ED8D2-F5E0-4A30-922E-574CF74E314AQ36580203-6E0EBF4C-98E3-420E-A0B9-CAA50F709F35Q36709551-23D585BC-5708-4D2D-BCCC-64BD3450808BQ36785507-9ECCA27D-7A84-4FAC-837F-3D4F8ECD4F4DQ36824825-B5E15E18-C1A0-4427-830E-DD1AF6B6E4B7Q36839797-CB9B80CE-55AB-4979-995C-14D1B0CD7274Q36954195-9C6CEF21-F151-4477-85D9-A4FE7823F01DQ37263452-64D4E450-199C-47D6-943A-B0F069F72D30Q37272623-4A9A43E3-C223-4761-848D-5DEED3D8ABD9Q37362560-FD0B0A98-9FA1-4108-AD7E-4F9BBBC8DD9DQ37407594-DFA0D4A4-490A-49ED-A4A0-2F8E442592B9Q37658764-B41BFF23-B2BA-4EC6-BAAF-27018960216AQ38561772-DB89B945-E10B-4793-B20F-182BF8EA3549Q38760738-C9843361-E7A5-4CD4-9EA1-60C408423C54Q39136071-0A703100-1C12-4B18-95CF-4D1C6BC55D1BQ39137843-2735EFAD-BB93-49D4-B302-CCD3961C1ABEQ39169780-5914B37C-9404-4BE5-91E0-9EA14E19F81FQ39340631-13561BA1-A05F-41EE-849B-7286BB98BE1AQ39418467-9E5848E8-94DF-436E-8B7A-DF429EC23ACAQ39475977-E89CCF65-373E-4C50-8F40-A02743307770Q39527047-C5611C54-EF37-4FF2-B83C-BE0AFC2079AEQ39617426-B1F68E47-D2AB-4AAD-AEF7-2ED689D52C77Q40134961-E251B0B7-6C8B-4CC6-84B1-08AB781632B3Q40403940-F351FC50-5248-49CC-B4F4-D18DE28E2238Q42367441-91265482-B88C-455E-9974-A8592CE3508BQ44364104-92662CF7-C21B-4E7E-AE4D-1E4C0B2C13FBQ45899687-65C5FAD5-D1F8-4222-841D-CCB1B8A87F8EQ51673654-7A5EB436-EC5D-481E-896B-5BD67F02FB0FQ53799129-57ED4682-6415-4B65-9A9E-611563354D8F
P2860
Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Frequent overexpression of mul ...... antibody immunity in patients.
@en
type
label
Frequent overexpression of mul ...... antibody immunity in patients.
@en
prefLabel
Frequent overexpression of mul ...... antibody immunity in patients.
@en
P2093
P2860
P50
P356
P1476
Frequent overexpression of mul ...... antibody immunity in patients
@en
P2093
Andrea Modesti
Domenico Vitolo
Laura Masuelli
Matthias H Kraus
Raffaella Muraro
Roberto Bei
Vanessa Ripavecchia
Vittore Cereda
P2860
P304
P356
10.1002/PATH.1642
P577
2004-11-01T00:00:00Z